ArticleInternational journal of laboratory hematology2026
Performance Evaluation of the Sysmex 'RBC Defect Workflow Optimisation' Flag for the Detection of Haemoglobinopathies and Iron Deficiency Anaemia.
Article in International journal of laboratory hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesHaemoglobinopathies are among the most common inherited disorders worldwide. Early detection of heterozygous carriers remains essential for appropriate diagnosis and counselling. The Sysmex 'RBC Defect Workflow Optimisation' (RWO) flag is a recently introduced automated tool designed to identify red cell abnormalities suggestive of heterozygous haemoglobinopathies (HGB HTZ), sickle cell disease (SCD), and iron deficiency anaemia (IDA). This study evaluated the diagnostic performance of the RWO flag in routine practice.
methodsOver 6 months (March-August 2025), 405 samples flagged by RWO (HGB HTZ, SCD, IDA) were prospectively evaluated, and positive predictive values (PPVs) were calculated. In addition, a retrospective analysis of the RWO HGB HTZ, SCD flag was performed on 122 consecutive haemoglobin analyses to assess diagnostic accuracy metrics. Finally, the HGB HTZ β-thalassaemia flag was compared with an external discriminant index, %MicroRBC/%HypoHe ratio (cut-off of 3.7).
resultsProspectively, the Sysmex RWO flag demonstrated PPVs of 81.9% for HGB HTZ, 68.7% for IDA, and 100% for SCD (n = 1). For IDA, PPV increased when analysis was restricted to different exclusion criteria. Retrospective sensitivity for HGB HTZ and SCD was only 25.0%, further clarified in this study. Diagnostic performance of the HGB HTZ β-thalassaemia flag was broadly comparable to that of the %MicroRBC/%HypoHe ratio.
conclusionsThe Sysmex RWO flag represents a feasible and effective screening tool for heterozygous haemoglobinopathies and sickle cell disease in routine clinical practice. Despite modest retrospective sensitivity, its high predictive value and workflow efficiency support its use as a trigger for targeted haemoglobin analysis in everyday laboratory diagnostics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.